PHARMARON (03759) shares tumbled nearly 3% following a profit warning announcement. At press time, the stock dipped 1.89% to HK$18.70, registering a turnover of HK$65.84 million. On July 15, the company disclosed projected H1 2025 revenue between RMB6.33 billion and RMB6.50 billion, marking a 13%-16% annual growth. Net profit attributable to shareholders is forecasted at RMB679 million to RMB713 million, plunging 36%-39% year-over-year. Excluding non-recurring items, net profit climbed 34%-39% to RMB624 million-RMB648 million, while adjusted non-IFRS net profit attributable to shareholders rose 6%-11%.
Mid-range projections indicate Q2 2025 revenue expanded 13.11% annually, with non-recurring-adjusted net profit surging 23.33% and adjusted non-IFRS net profit up 13.67%. The firm attributed the shareholder net profit contraction primarily to diminished non-recurring gains, despite sustained improvement in core operations. This profit slump contrasts sharply with robust underlying business performance, highlighting the impact of extraordinary item volatility on bottom-line results.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.